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SUMMARY
In an era where there is a shortage of lungs for transplantation is increased
utilization of lungs from donation after circulatory death (DCD) donors.
We review the reports of 11 controlled and 1 uncontrolled DCD programs
focusing on donor criteria, procedural criteria, graft assessment, and
preservation techniques including the use of ex vivo lung perfusion. We
have formulated conclusions and recommendations for each of these areas,
which were presented at the 6th International Conference on Organ Dona-
tion. A table of recommendations, the grade of recommendations, and ref-
erences are provided.
Transplant International 2016; 29: 790–797
Key words
donation after cardiac death, donation after circulatory death, guidelines, lung, nonheart beating
donation, review
Received: 13 May 2015; Revision requested: 2 August 2015; Accepted: 21 December 2015;
Published online: 15 January 2016
Introduction/background
The first lung transplantation was performed with an organ
recovered from a donation after circulatory death (DCD)
donor [1]. Renewed interest in DCD lung transplantation
was raised in the 1995 following the publication by
D’Alessandro and co-workers in which they reported the first
successful DCD donor lung transplantations as part of an
institutional DCD program [2]. They used DCD donors after
withdrawal of life support on an ICU, nowadays referred
to as controlled DCD (Maastricht DCD category III).
Further interest for DCD lung donation was trig-
gered by Steen and co-workers in 2001 who success-
fully transplanted a single lung from a donor after
failed cardiac resuscitation, a so-called uncontrolled
DCD donor [3]. In this case, the successful pretrans-
plant, ex vivo evaluation of graft function with a
machine, now called ex vivo lung perfusion (EVLP),
was a crucial step. EVLP allowed both subjective assess-
ment of donor lung function and prolongation of the
ischemic time (in this case to 17 h) simplifying the
logistics of transplantation in this unpredictable setting.
The basic principle of EVLP is the use of a preserva-
tion fluid with a high oncotic pressure, pure or mixed
with red blood cells (RBC), which is perfused by a
pump in a pressure-controlled manner into the
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pulmonary artery and recollected in a reservoir. The
perfusion fluid is gradually warmed to 37°C. Gentle
ventilation of the lungs is resumed for testing at 37°C
after the perfusate is deoxygenated with a N2/CO2 gas
mixture via a membrane gas exchanger inserted in the
circuit before it enters the pulmonary artery. The feasi-
bility to establish a successful uncontrolled DCD lung
transplant program was shown by the Madrid group
headed by A. Varela [4].
Today, 11 centers [5–23] have published results after
lung transplantation in a controlled DCD program.
Only the pioneering Madrid group have reported expe-
rience in an uncontrolled DCD program [4,24–28].
Recently, a working group within the International
Society for Heart and Lung Transplantation has taken
an initiative to collect multicenter data to gain insight
into selection, procedures, and outcome after DCD lung
donation). Over 300 DCD lung transplants were
included in the Registry, but it is likely that the total is
in excess of 450 worldwide [29].
This article is based on the reports of 11 controlled
DCD programs and the 1 uncontrolled DCD program.
We focus on donor criteria, procedural criteria, graft
assessment, and preservation techniques. For outcome
after DCD lung transplantation, these four steps are clo-
sely interlinked. Therefore, we formulated conclusions
and recommendations for each topic. These were dis-
cussed at the 6th International Conference on Organ
Donation in Paris in 2014. This article represents a
summary of the conclusions from this initiative.
Donor and procedural criteria
For controlled DCD lung donation, most centers use
the same donor criteria as for DBD donation. In addi-
tion, specific procedural criteria play an important role
in determining whether to accept the controlled DCD
lung or not. Clinical criteria for uncontrolled DCD lung
donation are scarce and based on a few patients.
Controlled DCD lung donation
The generally agreed DBD donor criteria for suitability
for transplantation form the background of the con-
trolled DCD donor criteria (Table 1). In addition, most
groups also use lungs from ‘extended’ criteria donors
defined as age > 65, smoking > 20 pack years, ICU
period > 5 days, and abnormal chest X-ray. A PO2/
FiO2 < 40 kPa is generally not accepted for DCD.
Functional criteria may be relaxed if EVLP is to be
used to recondition and evaluate the lungs. Significant
aspiration remains a contraindication but may be diffi-
cult to recognize, particularly if the first bronchoscopic
examination is carried out after death. It is important
to realize is that the criteria are applied in the situation
of a potential donor as the DCD procedure itself might
affect the value of the criteria. Therefore, although
arbitrary, specific procedural DCD criteria may play a
role such as heparin pretreatment, the allowed length of
the agonal phase, withdrawal of the tracheal tube, maxi-
mum length of initial warm ischemic period, timing of
re-inflation, and the use of EVLP. Of note using only
the period of warm ischemia is based on experimental
data alone [30], other factors are mainly based on clini-
cal practice. Recently, some centers advocate standard
ex vivo evaluation of graft function with EVLP for all
controlled DCD lungs [23].
Premortem ‘management’ in the donor
There are widely varying ethical frameworks for inter-
ventions in the premortem management of patients.
These need to reconcile appropriate treatment of the
patient who is not a donor until death occurs, with
good outcomes after transplantation, the presumed wish
of the patient, and the reason for considering donation.
Steps that are consistent with both aims are the most
acceptable. These should certainly include a mode of
ventilation which reduces lung injury (i.e., a tidal
volume of 6–8 ml/Kg ideal body weight, with PEEP of
8 cm H2O, frequent suctioning and appropriate recruit-
ment maneuvers). Ideally, they should also include a
premortem bronchoscopy, to assess the mucosa when
perfused and the placement of a naso-gastric tube.
Heparin pretreatment
Several centers reported good outcome without heparin
pretreatment. This is often based on ethical consideration
[16,20,22]. Importantly, these centers all use retrograde
flushing during preservation. In assessing this heparin-
free scenario, no emboli or thrombi could be detected
in DCD lungs that were harvested to search for
Table 1. DCD donor criteria.
Age <65 years
Smoking <20 pack years
Chest X-ray Clear
Mechanical ventilation <5 days
Blood transfusion <5 units RBC
Oxygenation PO2 > 40 kPa
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thrombo-embolic lesions by pathologic and histopatho-
logic investigation [31]. Other centers do use heparin pre-
treatment of the potential DCD donor [5,7,10,11].
Experimentally, pretreatment with heparin of DCD donor
lungs was shown to be beneficial in a way that it prevented
worsening of lung function during EVLP [32]. No clinical
study is available comparing both strategies. With current
data and criteria available, no conclusion can be drawn.
Theoretically, heparin pretreatment seems to be beneficial.
The agonal phase
The maximal length of the agonal phase (withdrawal of
life support until circulatory arrest) is arbitrarily set at
2 h. There is no information to determine the maximal
save length of the agonal phase for lungs based on clinical
research. Multiple definitions of agonal phase are
described in the literature. The most often used definition
for the agonal phase in papers concerning lung transplan-
tation is the period between withdrawal of life support
and the declaration of death. Definitions and criteria to
declare a donor death might, however, differ between
countries and centers (e.g., absent peripheral pulsation,
flat ECG). For lungs, re-inflation might be an important
extra step in the agonal phase, most often before flush
perfusion. It is well known that inflation is an effective
preservation method to maintain lung cell viability. In
practice, the duration of the agonal phase is greatly based
on logistics of the procedure. A waiting time of more
than 2 h is generally too significant of a workforce bur-
den. As shown in kidney DCD donation, the save agonal
phase might be influenced by injury caused by hypoten-
sion after withdrawal of life support [33]. The Leuven
group in an experimental model of porcine EVLP
demonstrated that pulmonary function is worse in lungs
coming from donors dying from hypoxic cardiac arrest
(mimicking clinical situation in controlled donation after
ventilator switch off) compared to exsanguination and
acute ventricular fibrillation (mimicking clinical situation
in uncontrolled donation) [34]. Only one clinical study
[22] showed a slightly worsening oxygenation capacity of
transplanted controlled DCD lungs when the period from
the start of hypotension (RR < 6.6 KPa [50 mm Hg]) till
circulatory arrest became longer during the agonal phase.
Withdrawal of tracheal tube
Good results are reported with or without withdrawal
of the tube. There is no clear consensus whether with-
drawal of the tracheal tube is harmful or beneficial for
the process. It might protect the airways for aspiration,
but it also might prolong the agonal phase by prevent-
ing a collapse of the upper airway with asphyxia of the
donor.
Maximum length of initial warm ischemic period
The initial warm ischemic period, defined as the period
after circulatory arrest and start of flush perfusion
preservation, reported in clinical series is approximately
30 min. Nevertheless, success is reported in cases with
a period up to 93 min [15]. Most centers have proto-
cols with a maximum tolerable length of initial warm
ischemic period of 1 h based on experimental data
[30].
Lung preservation in case of normothermic regional
perfusion (NRP) of the abdominal organs
A number of liver teams have introduced perfusion of
the abdominal organs with oxygenated blood, using an
ECMO-like circuit. Clamping of the descending aorta to
prevent any possibility of restarting brain perfusion is
an absolute requirement. The abdominal team will can-
nulate the abdominal aorta and IVC, and the cardiotho-
racic team will then clamp the lower thoracic aorta and
then immediately proceed to flush the lungs in vivo.
Limited topical cooling should be used. The intraperi-
cardial IVC should be clamped at an early stage to
reduce the chance of entraining air into the perfusion
circuit. While abdominal perfusion continues, the tho-
racic team removes the lungs, for retrograde perfusion
on the back table. Ensuring complete hemostasis in the
chest, given the donor is systemically heparinized, is
important [35].
Ex vivo lung perfusion
Recently, the Toronto group advocated the use of EVLP
for all controlled DCD donors [23]. Nine DCD lung
transplantations were performed. There is, however, no
detailed information about the specific behavior or
injury of the 9 controlled DCD lungs during EVLP eval-
uation. The growing evidence that EVLP improves sub-
optimal lungs supports the use of EVLP after controlled
DCD donation, especially when the outer ranges of
accepted criteria are applied.
Uncontrolled DCD lung donation
The Madrid group is currently the only group who has
reported clinical experience with uncontrolled DCD
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lung transplantations [27]. Using the procedural criteria
of acceptable cold in vivo blood gas measurement and
acceptable visual inspection, they reported on 29 trans-
plantations with uncontrolled DCD lungs. This led to a
similar 1-year survival but to a higher percentage of pri-
mary graft dysfunction as compared to results in their
DBD program. The group is now investigating the use
of EVLP on the OCS LungTM device as a tool to assess
and to condition the pulmonary graft prior to trans-
plantation [36]. Stig Steen (Lund, Sweden) was the first
author to report in 2001 in a detailed way on a success-
ful transplantation of lungs from an uncontrolled DCD
after EVLP [3].
Uncontrolled DCD lung donor criteria (as used by
the Madrid group) reference
1. Witnessed cardiac arrest.
2. Basic and advanced resuscitation maneuvers within
15 min.
3. Continuing resuscitation during transportation.
4. Decision on failed resuscitation and declaration of
death by ICU personnel.
5. Legal permission to proceed with donation.
6. Adequate blood gas measurement with in vivo single
flush technique (53.3 KPa [400 mm Hg] or above
corrected for temperature) and acceptable at visual
lung inspection (collapse test, correct flushing, no
thrombi on retrograde perfusion, etc.).
7. Chest X-ray on ICU.
8. Age 7–70 years.
9. No specific contraindications other than for DBD
lung donation.
Uncontrolled DCD lung procedural criteria
1. A total warm ischemia time (cardiac arrest + resus-
citation + 5 min hands-off, ventilatory, and circula-
tory support until start of topical cooling) of
maximal 120 min. This arbitrary period of warm
ischemia was adopted by the Madrid group as the
adequacy of lung perfusion during resuscitation is
unknown. The ‘true warm ischemia time’ starting at
end of resuscitation was not defined but is probably
of importance.
2. In vivo topical cooling period of up to 240 min. The
cooling fluid returning from the pleura should reach
a temperature below the 21°C (personal communica-
tion). To control the cooling of the lungs is of speci-
fic importance when normothermic iRP of the
abdominal organs is performed as described above.
Using above criteria, 40% of lungs are rejected after cold
in vivo blood gas measurement and visual lung inspection.
Steen et al. mentioned in their case report an age
below 70 years and an initial warm ischemic period of
1 h as acceptable for transplantation after uncontrolled
DCD donation. EVLP was used for lung validation and
preservation. No specific EVLP criteria to decide on
uncontrolled DCD lung function are yet available.
Pulmonary graft assessment and preservation
techniques
Controlled DCD lung donation
Traditionally in heart beating brain-dead donors (DBD),
lung function is validated before the donation procedure.
This is made by interpretation of the partial oxygen pres-
sure (PaO2) in relation to the percentage-inhaled oxygen
(FiO2) in a peripheral arterial blood sample and ventila-
tion pressure settings (PEEP 5 cm H2O). The same
validation technique is being used for controlled DCD
lung donation although potentially, the cessation of venti-
lation and circulation and the subsequent unavoidable
period of warm ischemia may decrease the quality of the
DCD lung. To preserve the lung in the period between cir-
culatory arrest and cold flush preservation with the lung
untouched in the thorax of the donor, topical cooling
might be used [3]. To be successful, the preceding period
of warm ischemia should be within 1 h as stated earlier
[29]. Because of the uncertain effect of this period, some
groups advocate the use of EVLP in the setting of con-
trolled DCD lung donation. EVLP enables pulmonary
graft validation after the potentially inflicted injury and,
importantly, before implantation.
Lung function validation in the donor
Most groups in Europe and the USA successfully use
the lung validation technique in the donor for DCD as
used for DBD donation after BD [5–22]. The lung func-
tion validation is based on measurement of the PO2 at
a FiO2 of 100% oxygen with a standardized PEEP of
5 cm H2O during mechanical ventilation. Generally, a
cutoff point of >40 kPa (300 mm Hg) is used to accept
the lungs. Important prerequisites that are reported in
combination with this method are as follows:
1. An agonal phase not exceeding 2 h (period between
stop treatment and circulatory arrest).
2. A warm ischemia time (WIT) (time between circula-
tory arrest and start flush perfusion preservation) of
30 min or shorter.
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As part of graft evaluation, inspection of the pul-
monary artery for possible clots and of deflation of the
lungs during a collapse test is recommended. Based on
these methods, the immediate pulmonary graft function
of DCD lungs is comparable to DBD lungs [15–
18,21,22]. As scaled with the primary graft dysfunction
(PGD) score proposed by the ISHLT, PGD grades after
controlled DCD donation are found to be similar to
those after DBD donation and transplantation
[16,17,22].
Lung preservation
Measures to improve preservation might already start
before withdrawal of life support. Some centers admin-
ister heparin iv to the donor. As described above in the
procedural criteria, till now no differences in outcome
are seen between series with or without heparin. Topi-
cal cooling might be used in controlled DCD, but is
not often described. The most used method of preser-
vation is flush perfusion although no clinical studies
are available on the best flush solution and on the best
flush route (antegrade versus retrograde) for DCD
lungs. The Leuven group has demonstrated in a porcine
model evaluating DCD pulmonary function during
EVLP that in vivo topical cooling was effective up to
7 h after circulatory arrest including 90-min warm
ischemia [37]. In another study from the same group
using the same model, it was demonstrated that retro-
grade flush of DCD lungs was superior compared to
antegrade flush after both warm ischemia [38] and after
topical cooling [39]. The current clinical practice is
antegrade and retrograde flush with Perfadex, Celsior,
or UW as mostly used flush solutions. The antegrade
flush is performed during slow ventilation or inflation.
The retrograde flush is performed on a back table by
cannulating four lung veins separately. Lungs are stored
inflated on ice.
Ex vivo lung perfusion
The Toronto group was the first to use EVLP in a
standard fashion for controlled DCD lungs. Their ser-
ies compromise till now 22 controlled DCD lungs
that were perfused and ventilated for 4–6 h and
transplanted successfully [23]. Four DCD lungs did
not meet the acceptance criteria and were rejected
after EVLP. Ten of the 22 successfully transplanted
DCD lungs would normally have been rejected due to
low oxygenation capacity while ventilated in the
donor but were judge suitable after EVLP. A recent
experimental study from the same group looking at
pulmonary function in a porcine model after 10 h
brain death and 24 h cold ischemia demonstrated that
an ex vivo measured low PO2 during EVLP may not
be the first indicator of lung injury and, taken alone,
may be misleading in assessing the ex vivo lung.
Thus, evaluation of other physiologic parameters like
compliance and pulmonary vascular resistance during
EVLP takes on greater importance [40].
Uncontrolled DCD lung donation
In uncontrolled DCD lung donation, a method to vali-
date lung function after donation is a necessity as lung
function is unknown before donation. EVLP is thought
to be a good method to evaluate lungs from uncon-
trolled DCD donors. However, the largest experience
with lung validation in uncontrolled DCD is with an
in vivo single flush technique as described by the
Madrid group.
Lung preservation
After failed resuscitation and certification of death,
lungs will suffer an obligatory period of warm ischemia.
As described by the Madrid group, this expands up to
2 h [26]. After this period, chest tubes are inserted for
topical lung cooling [3,26] and the patient can be con-
nected to a veno-arterial ECMO system via catheters
inserted in the groin for preservation of abdominal
organs. The subsequent generally used flush perfusion is
already described in the Controlled DCD section. The
retrograde flush might be of great importance in pro-
grams not using heparin before withdrawal of life sup-
port. The method for lung preservation differs for
category IV DCD, where the heart stops prematurely
during organ retrieval in a brain-dead patient and prior
to aortic cross-clamp and cardioplegia. In this infre-
quent, uncontrolled DCD category a cannula can be
rapidly inserted in the pulmonary artery for cold flush
perfusion.
In vivo single flush lung validation technique
The in vivo single flush technique is a very simple and
practical method. It is used after heparinization of the
donor that is circulated with some extra chest com-
pressions. After topical lung cooling and subsequent
sternotomy and antegrade flush perfusion preservation
of the lungs, 300 ml of 4–10°C donor blood is flushed
via the pulmonary artery while the lungs are ventilated
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with 100% oxygen. The blood is collected from the
lung veins and the PO2 is measured and corrected for
the temperature used during flushing. Cutoff point for
PO2 is <53.3 KPa (400 mm Hg). Acceptance of the
lung was further based on visual appearance (collapse
test, correct flushing, no thrombi on retrograde
perfusion. . .). Results are described of 29 to 32 uncon-
trolled DCD lung transplantations. Due to higher
incidence of PGD and early mortality compared to
DBD donation with this in vivo single flush technique,
the Madrid group now recommends that some
form of ex vivo validation of pulmonary graft func-
tion should be adopted in uncontrolled DCD lung
donation.
Ex vivo lung perfusion
There are only two clinical reports on EVLP in the
situation of uncontrolled DCD donation [3,32]. In the
first case report by the group of Stig Steen EVLP
showed excellent performance of the uncontrolled
DCD lung. The subsequent single lung transplantation
procedure was successful. The basic principle of EVLP
is the use of a preservation fluid with a high oncotic
pressure mixed with RBC’s that is perfused by a pump
in a pressure-controlled way into the pulmonary artery
and recollected in a reservoir. The perfusion fluid is
gradually warmed to 37°C. Gentle ventilation the lungs
is resumed for testing at 37°C after the perfusate is
deoxygenated with a N2/CO2 gas mixture via a mem-
brane gas exchanger inserted in the circuit before it
enters the pulmonary artery. Recently, the Madrid
group reported their experience with EVLP for valida-
tion of uncontrolled DCD lungs during the 2011
annual meeting of the ISHLT in San Diego (32 = 34
n). Besides PaO2, lung compliance and ventilatory
pressures might be important parameters to evaluate
graft quality similar to EVLP after controlled DCD
donation [36].
Conclusions and recommendations
Controlled DCD
The current use of the same DBD donor criteria in
controlled DCD results in good lung transplant out-
come. Pulmonary graft validation in the donor leads
to good results. Combined antegrade and retrograde
flush perfusion and inflated storage do preserve the
DCD lung as good as the DBD lung. This is true
regardless of the use of heparin or withdrawal of the
tracheal tube but with a time between withdrawal of
treatment and circulatory arrest of <90 min and an
initial warm ischemic period of <60 min. EVLP was
shown to be beneficial in extending donor criteria and
in using donor lungs with initially unacceptable PO2.
Results for DCD lung transplants have been shown in
a large number of reports and summarized in a recent
meta-analysis [41], to be essentially identical to those
from DBD donors. The single, and as yet unconfirmed
dissenting report, suggests a slightly higher incidence
of PGD and a higher risk of early bronchiolitis
obliterans [42].
Uncontrolled DCD
Uncontrolled lung donation has shown to be successful
using general criteria and strict procedural criteria with
the help of in vivo pulmonary graft testing, visual
inspection, and chest X-ray investigation. However, out-
come remains somewhat inferior as compared to DBD
lung transplantation. The use of EVLP to validate and
preserve the lung is still under investigation. Combined
topical cooling and flush perfusion is currently the only
described preservation method.
Recommendation table DCD lung
Recommendation Grade References
Use same donor selection criteria
for DCD as already established
for DBD.
B [5–23]
DCD lungs should not be
discarded as quality and outcome
is at least similar to DBD lungs.
B [5–23]
Perform antegrade and retrograde
flush perfusion.
C [35–37]
Use same terminology and
definition for warm ischemia
times as used for other organs
D
Protect the airway early after
declaration of death to avoid
aspiration during abdominal
organ retrieval.
D
Pretransplant ex vivo lung
perfusion (EVLP) is advised in
case of uncertain graft
performance to safely extend
donor and procedural criteria
(long WI, bad flush, clots), lungs
with a PO2/FiO2 < 40 kPa and/or
agonal phase >90 min and/or
warm ischemia >60 min might
be used after testing with EVLP.
C–D [23]
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Continued.
Recommendation Grade References
Acceptance criteria on EVLP may
include measures of pulmonary
compliance, vascular resistance,
and gas exchange.
C [23,31,34]
Uncontrolled DCD lung donation
should adhere to the strict
procedural criteria of
[3,4,24–28,34]
1. Witnessed cardiac arrest. D
2. Basic and advanced
resuscitation maneuvers within
15 min.
D
3. Continued resuscitation during
transport of potential donor.
D
4. Total warm ischemia period
(cardiac arrest – start
preservation) should be
<120 min.
D
5. Effective in vivo topical cooling
prior to flush preservation 20°C.
D
6. Transplant suitability of these
lungs should in general be tested
ex vivo using EVLP before
acceptance based on measures
of pulmonary compliance,
vascular resistance, and gas
exchange.
D
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